Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information visit www.olink.com
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information visit www.olink.com
Location: United States, Massachusetts, Watertown
Employees: 201-500
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Beijer Ven... | beijervent... |
| - | Summa Equi... | summaequit... |
Mentions in press and media 10
| Date | Title | Description |
| 31.10.2024 | The Rise of Biomarkers: Navigating the Future of Personalized Medicine | In the realm of healthcare, biomarkers are the new compass. They guide us through the complex landscape of disease and treatment. As we delve deeper into the world of biomarkers, particularly protein biomarkers, we uncover their potential t... |
| 29.10.2024 | What is a Good Biomarker? Upcoming Webinar Hosted by Xtalks | www.olink.com In this free webinar, gain insights into the invaluable and increasing role of protein biomarkers in healthcare. The featured speakers will discuss the critical steps and considerations in the biomarker development pipeline. T... |
| 21.09.2024 | The Intersection of Science and Investment: Olink Proteomics and Schroders Capital's Strategic Moves | In the ever-evolving landscape of science and finance, two stories stand out: Olink Proteomics and Schroders Capital. Both entities are making waves, but in different arenas. Olink is pushing the boundaries of proteomics, while Schroders is... |
| 20.09.2024 | Olink Proteomics Announces the 'Olink Proteomics World' Virtual Conference: A Novel Platform Exploring the Latest Advancements in Proteomics and Proteogenomics | Olink Proteomics World Virtual Event September 26th, 2024 The 'Olink Proteomics World' Virtual Conference will bring together scientists from around the globe to explore the latest advancements in proteomics and proteogenomics across fields... |
| 19.09.2024 | Schroders Capital Raises $2.6 Billion In Private Equity Direct And Co-Investments | Schroders Capital, a leading $97.3 billion private markets business of Schroders Group, announced it has achieved a significant funding milestone. Since January 2022, it has successfully raised over $2.6 billion for direct and co-investment... |
| 13.05.2024 | Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK | BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further i... |
| 23.04.2024 | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization Tue, Apr 23, 2024 07:52 CET Report this content Capitainer, a leading Swedish medtech company that specializes in user-friendly self-sampling soluti... |
| 08.03.2024 | Olink announces change of date for Annual General Meeting | - |
| 07.03.2023 | NUS Medicine Implements Olink Technology To Accelerate Precision Medicine Through Next-generation Proteomics | Olink Holding AB announced that the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink Explore 3072, Olink E... |
| 31.08.2021 | CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services | MONTRÉAL, Aug. 31, 2021 /PRNewswire/ -- CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quan... |